Analysis Group Team Conducts One of First Studies to Focus on Clinical and Economic Burden of US Patients with Multiple Myeloma and Renal Impairment
August 27, 2024
An estimated 61% of patients with multiple myeloma (MM) are diagnosed with renal impairment within the first year of their initial diagnosis, a condition associated with complications that worsens their prognosis. In spite of this, evidence on real-world clinical and economic outcomes in US patients with MM and RI is scarce, and data on these patients are limited. To fill this gap, Analysis Group consultants, in collaboration with researchers from Sanofi and the Medical College of Wisconsin, performed a retrospective claims study to create one of the first updated, comprehensive assessments of the total clinical and socioeconomic burden of these high-risk and challenging-to-treat patients in the US.
In the study, Managing Principal Annie Guérin, Vice President Dominick Latrémouille-Viau, and their collaborators drew on Medicare Part D data to analyze treatment patterns and clinical outcomes in MM patients, with a focus on those with renal impairment. The researchers used an overall MM cohort as a reference and reviewed patterns in patients with MM and renal impairment from first-line to fourth-line therapy. They found that MM patients with renal impairment had worse clinical outcomes – including shorter progression-free and overall survival and higher health care resource utilization than the overall referent cohort of MM patients, demonstrating a considerable unmet need in these patients. Additionally, the researchers’ analysis of these patients’ treatments suggests that administering newer, high-efficacy therapies earlier in the treatment pathway could, in spite of higher treatment costs, improve clinical outcomes for this high-risk population.
The study, “Clinical and economic burden of medicare beneficiaries with multiple myeloma and renal impairment,” appeared in Medicine in May 2024.